How should we do in the selection and follow-up of systemic conventional treatments in psoriasis?

Exploration of Musculoskeletal Diseases, vol.1, pp.241-256, 2023 (Peer-Reviewed Journal)

There is an increasing need for appropriate effective treatment and long-term disease control in patients

with psoriasis because of the decreased quality of life, increased physicosocial deficits and associated comorbidities.

Systemic conventional treatments that are the first step in the management of moderate-tosevere

plaque psoriasis include methotrexate (MTX), acitretin, cyclosporine and fumarates. MTX is

considered the gold standard in the treatment of moderate-to-severe chronic plaque type psoriasis. It is

also used to treat pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis. Acitretin monotherapy

is less effective than other conventional systemic treatments for plaque psoriasis, while superior to

generalized, palmoplantar pustular, and hyperkeratotic variants. Cyclosporine is preferred in the presence

of unstable acute clinical conditions (erythrodermic or generalized pustular psoriasis) and also in induction

phase of rotational and sequential therapy for severe resistant psoriasis, due to its rapid effect. Dimethyl

fumarate, which has similar efficacy to MTX, is an appropriate option in the induction and long-term

systemic treatment for adult patients with moderate to severe plaque psoriasis without psoriatic arthritis.

Although they are often overshadowed by biologics at the stage of preference by most physicians and

patients today, they are classical and inexpensive agents with known long-term results. When the

appropriate patient profile and psoriasis type are selected at the right time and necessary laboratory and

clinical follow-ups are made, each of them is an effective treatment with reliable and satisfactory results. In

this article, important points (recommendations according to patient characteristics, psoriasis type and

comorbidities) to be considered in clinical practice when using the conventional anti-psoriatic agents in the

treatment of psoriasis are overviewed.